In another case, we detected a mutation in PIM1 (Table 1, No. 3), which is postulated to represent a potential negative predictive factor for ibrutinib therapy in the activated B‐cell subtype of DLBCL.3, 15. This evidence concerns the gene PIM1 and diffuse large B-cell lymphoma.